Insider’s Confidence in Regulus Therapeutics (RGLS); Micron Technology (MU) Beats Profit Expectations
Shares of Regulus Therapeutics Inc. (Nasdaq:RGLS) climbed 12.00% (or +$0.15) to $1.40 on Friday’s trading session after its Chairman of the Board, Stelios B. Papadopoulos, disclosed in a regulatory filing ( FORM 4 ) with the Securities and Exchange Commission (SEC) that he purchased recently 200,000 shares (at an average price of $1.199 each) and 300,000 shares (at an average price of $1.227 each) of the biopharmaceutical company.
Earlier this month, the company reported fourth quarter 2016 revenue of $18,000 and a net loss of ($20.02) million, or ($0.38) per share for the period.
Regulus Therapeutics,which focuses on the discovery and development of drugs that target RNAs to treat a range of diseases, has 52.93M shares outstanding, market capitalization (intraday) of $74.11M and and RGLS stock 52-week range is from $0.94 to $8.90 per share.
Micron Technology, Inc. (Nasdaq:MU) shares soared to touch a new 52-week high of $29.87 in intraday trading Friday after the company delivered stronger-than-expected quarterly profit numbers in its financial results.
For its second quarter fiscal 2017, Micron posted revenues of $4.65 billion, a 58% increase year over year, and non-GAAP net income of $1.03 billion, or $0.90 per diluted share, compared to non-GAAP net income of $12 million, or $0.01 per diluted share in the same quarter the prior year, topping the Capital IQ Consensus Estimate of $0.86 earnings per share on revenues of $4.65 billion for the period
MU stock closed at $28.43, up $1.96 (or +7.40%) with a total volume of 107.48M shares traded during the day, representing a large increase in activity verus its average volume (3m) of 26.45M shares.
Micron Technology, which provides semiconductor systems worldwide, has 1.10B shares outstanding, market capitalization (intraday) of $31.35B and MU stock one-year range is now between $9.35 and $29.87 per share.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/